Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, doubleblind, placebo-controlled, multicenter trial
SM Opal, CJ Fisher, JFA Dhainaut, JL Vincent… - Critical care …, 1997 - journals.lww.com
Objective To determine the therapeutic efficacy and safety of recombinant human interleukin-
1 receptor antagonist (rhIL-1ra) in the treatment of patients with severe sepsis. Design
Prospective, randomized, double-blind, placebo-controlled, multicenter trial with a planned,
midstudy, interim analysis.
1 receptor antagonist (rhIL-1ra) in the treatment of patients with severe sepsis. Design
Prospective, randomized, double-blind, placebo-controlled, multicenter trial with a planned,
midstudy, interim analysis.